Loading clinical trials...
Loading clinical trials...
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Conditions
Interventions
FWY003
Placebo
Locations
7
United States
Salehi Retina Institute
Huntington Beach, California, United States
Advanced Research LLC
Boynton Beach, Florida, United States
Advanced Research LLC
Deerfield Beach, Florida, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
Opthamalic Consultants of Boston
Boston, Massachusetts, United States
Novartis Investigative Site
Albury, New South Wales, Australia
Start Date
March 9, 2026
Primary Completion Date
August 21, 2029
Completion Date
August 22, 2029
Last Updated
April 6, 2026
NCT07144137
NCT07392255
NCT06990269
NCT07424235
NCT04770545
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions